|
⚲
|
| Keyboard |
| Hatteras Venture Advisors III LLC
✚
|
|
|---|---|
| CRD # | 161495 |
| SEC # | 802-75759 |
| CIK # | 0001674177 |
| AUM | |
| Employees | |
| Phone | 919-484-0730 |
| Address | 280 S Mangum St Durham, NC 27701 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | Hatteras Venture Affiliates III LP | [2012-03-30] | 2.3 M | |
| VC | Hatteras Venture Partners III LP | [2012-03-30] | 6.4 M |
| AUM Breakdown | Accounts | AUM ($) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 0 | 0.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Discretionary | ||
| Discretionary | 0 | 0.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 0.0 | |
| Total | 0 | 0.0 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001674177] | |
| 4 | [0001674177] | |
| SC 13D | [0001674177] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Hatteras Venture Advisors III LLC | PhaseBio Pharmaceuticals Inc | [2018-11-01] |
| Hatteras Venture Advisors III LLC | Clearside Biomedical Inc | [2016-06-17] |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
PhaseBio Pharmaceuticals Inc PHAS
Series B Preferred Stock · derivative
|
2018-10-22 | Sell | 42 | $5.00 | 210 |
|
PhaseBio Pharmaceuticals Inc PHAS
Series B Preferred Stock · derivative
|
2018-10-22 | Option exercise | 19,061 | $0.12 | 2,287 |
|
PhaseBio Pharmaceuticals Inc PHAS
Series B Preferred Stock · derivative
|
2018-10-22 | Sell | 458 | $5.00 | 2,290 |
|
PhaseBio Pharmaceuticals Inc PHAS
Warrants to Purchase Series B Preferred Stock · derivative
|
2018-10-22 | Option exercise | 1,731 | $0.00 | |
|
PhaseBio Pharmaceuticals Inc PHAS
Series B Preferred Stock · derivative
|
2018-10-22 | Option exercise | 1,731 | $0.12 | 208 |
|
PhaseBio Pharmaceuticals Inc PHAS
Warrants to Purchase Series C-1 Preferred Stock · derivative
|
2018-10-22 | Option exercise | 47,458 | $0.00 | |
|
PhaseBio Pharmaceuticals Inc PHAS
Series C-1 Preferred Stock · derivative
|
2018-10-22 | Option exercise | 47,458 | $0.12 | 5,695 |
|
PhaseBio Pharmaceuticals Inc PHAS
Series C-1 Preferred Stock · derivative
|
2018-10-22 | Sell | 1,139 | $5.00 | 5,695 |
|
PhaseBio Pharmaceuticals Inc PHAS
Warrants to Purchase Series C-1 Preferred Stock · derivative
|
2018-10-22 | Option exercise | 4,309 | $0.00 | |
|
PhaseBio Pharmaceuticals Inc PHAS
Series C-1 Preferred Stock · derivative
|
2018-10-22 | Option exercise | 4,309 | $0.12 | 517 |
|
PhaseBio Pharmaceuticals Inc PHAS
Series C-1 Preferred Stock · derivative
|
2018-10-22 | Sell | 104 | $5.00 | 520 |
|
PhaseBio Pharmaceuticals Inc PHAS
Series C-1 Preferred Stock · derivative
|
2018-10-22 | Option exercise | 41,414 | $0.12 | 4,970 |
|
PhaseBio Pharmaceuticals Inc PHAS
Series C-1 Preferred Stock · derivative
|
2018-10-22 | Sell | 994 | $5.00 | 4,970 |
|
PhaseBio Pharmaceuticals Inc PHAS
Series 1 Preferred Stock · derivative
|
2018-10-22 | Conversion | 52,690 | $0.00 | |
|
PhaseBio Pharmaceuticals Inc PHAS
Common Stock
|
2018-10-22 | Conversion | 1,683,420 | ||
|
PhaseBio Pharmaceuticals Inc PHAS
Common Stock
|
2018-10-22 | Buy | 150,000 | $5.00 | 750,000 |
|
PhaseBio Pharmaceuticals Inc PHAS
Common Stock
|
2018-10-22 | Conversion | 52,690 | ||
|
PhaseBio Pharmaceuticals Inc PHAS
Common Stock
|
2018-10-22 | Conversion | 266,481 | ||
|
PhaseBio Pharmaceuticals Inc PHAS
Common Stock
|
2018-10-22 | Buy | 137,513 | $5.00 | 687,565 |
|
PhaseBio Pharmaceuticals Inc PHAS
Common Stock
|
2018-10-22 | Conversion | 150,612 | ||
| showing 20 of 50 most recent transactions | |||||